Skin boosters and dermal fillers: the clinical differences

Practitioners field the same question from patients weekly: "filler or skin booster?" The two product classes share one molecule, hyaluronic acid, and almost nothing else. Cross-linking chemistry, injection plane, indication, and maintenance schedule all diverge. This guide sets out the clinical differences that decide which class belongs in a treatment plan, and the CE-marking rules that apply to each in Portugal and Spain.

The chemistry: cross-linked vs non-crosslinked HA

A dermal filler is HA that has been chemically cross-linked, typically with BDDE — in Sofiderm's case through the multiphase MCLPE process, into a cohesive gel. Cross-linking converts free HA chains into a three-dimensional matrix with measurable elasticity (G' modulus) and lift capacity. The gel resists enzymatic degradation, which is what gives fillers a 6 to 24-month duration.

A skin booster is HA with little or no cross-linking, at lower viscosity, often combined with bioactive components. It cannot lift or volumise. Its purpose is different: rehydration of the dermis, improved elasticity, and stimulation of fibroblast activity. Free HA binds many times its weight in water, so the clinical effect is tissue quality, not tissue volume.

Injection plane and technique

Fillers are placed where structure is needed: mid-to-deep dermis, supraperiosteal or subcutaneous, according to the plane the device's indication provides for. Placement is point-specific, bolus, linear threading, or fanning at defined depths.

Skin boosters are placed superficially, intradermal micro-boluses (typically 0.02 to 0.05 ml per point) across a grid, or with multi-needle devices. The target is the dermal layer itself, not a fold or a deficit. Treating a nasolabial fold with a skin booster under-corrects it; volumising the dermis with a cross-linked filler risks nodules and surface irregularity.

Practical rule: fillers treat a location (a fold, a contour deficit); skin boosters treat a surface (crepey cheeks, dull decollete, dehydrated perioral skin). If the indication reads as an area rather than a point, a booster-class product is usually the right tool.

Where each class works

Each device's indications are those of its CE certificate and are listed on the line's own page. As classes, and without tying them to any product: cross-linked fillers correct a contour deficit at a point; skin boosters treat the quality of a surface — fine crepey texture, dull or dehydrated skin. They are also used to condition skin before or between filler sessions.

Duration and maintenance

Cross-linked fillers hold 6 to 24 months depending on cross-linking density, G', and injection area. Retreatment is corrective: you re-treat when volume fades.

Skin boosters follow an induction-plus-maintenance model: typically 2 to 3 sessions spaced 2 to 4 weeks apart, then a single maintenance session every 4 to 6 months. Communicating this schedule at consultation is essential. A patient expecting a one-session result from a booster protocol will read a normal treatment course as a failure.

Reversibility and safety profile

Both classes are HA and both respond to hyaluronidase, but the risk profiles differ. Fillers carry the vascular risks of deep injection, occlusion being the emergency scenario every injector trains for. Skin boosters, placed intradermally in micro-volumes, have a lower vascular risk profile; their typical adverse events are papules from too-superficial deposits and transient injection-site reactions. An emergency hyaluronidase protocol remains a requirement for any clinic injecting either class.

What CE marking means for each class

Under EU MDR 2017/745, injectable HA products for aesthetic indications are Class III medical devices, the highest risk class, requiring notified-body assessment of clinical safety, biocompatibility and sterility. This applies to skin boosters exactly as it does to fillers: "it is only a booster" does not place a product in a lower class.

Before adding any injectable to a treatment menu, verify: the CE certificate and notified body number, the product's registration status with INFARMED (Portugal) or AEMPS (Spain), batch-level traceability documentation, and continuous storage at 2–30 °C attestation. The distributor obligations of MDR Article 14 apply to the full supply chain regardless of product class. A summary of what to demand from any supplier is in our supplier checklist.

Combining both classes in one plan

The classes are complementary, not competing. A common sequence: structural correction first (filler, one session), then a booster induction course beginning 2 to 4 weeks later to address skin quality over the corrected foundation. Documenting the plan by class, structure vs surface, keeps patient expectations aligned with what each product can biologically deliver.

For the underlying HA science, molecular weight, cross-linking chemistry, and rheology, see our science overview. To review the CE-marked Sofiderm filler range available to clinics in Portugal and Spain, see the product catalogue.

This article is informative and intended for healthcare professionals. It does not replace the instructions for use or clinical judgement. Sources: Regulation (EU) 2017/745, articles 14 and 25; manufacturer documentation; Orvida internal procedures.